Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
12.15
-0.40 (-3.19%)
At close: Mar 28, 2025, 4:00 PM
12.53
+0.38 (3.16%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Nurix Therapeutics Revenue
In the fiscal year ending November 30, 2024, Nurix Therapeutics had annual revenue of $54.55M, down -29.15%. Nurix Therapeutics had revenue of $13.28M in the quarter ending November 30, 2024, a decrease of -12.37%.
Revenue (ttm)
$54.55M
Revenue Growth
-29.15%
P/S Ratio
14.95
Revenue / Employee
$190,731
Employees
286
Market Cap
922.02M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NRIX News
- 5 days ago - Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting - GlobeNewsWire
- 13 days ago - Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia - GlobeNewsWire
- 16 days ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch. - GlobeNewsWire
- 26 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer - GlobeNewsWire